[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356684-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356684-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-pilot-study-of-18frhpsma73petmri-to-reduce-mischaracterization-of-active-surveillance-and-focal-therapy-candidates-with-occult-higher-risk-disease","A Pilot Study of 18F‐rhPSMA‐7.3‐PET/MRI to Reduce Mischaracterization of Active Surveillance and Focal Therapy Candidates With Occult Higher Risk Disease","","PSMA-PET provides an opportunity to reduce mischaracterization of disease in active surveillance (AS) and focal therapy (FT) candidates. A pilot clinical trial evaluated 18F-radiohybrid (rh)PSMA-7.3 PET/MRI for detecting occult adverse pathology among men meeting MRI-informed biopsy criteria. Twenty participants with low or favorable intermediate risk disease underwent PET/MRI followed by biopsy or radical prostatectomy within 90 days, assessing detection of higher-grade pathology. Post-scan confidence increased significantly and management changed in a substantial fraction of patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-pilot-study-of-18frhpsma73petmri-to-reduce-mischaracterization-of-active-surveillance-and-focal-therapy-candidates-with-occult-higher-risk-disease/356684/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-pilot-study-of-18frhpsma73petmri-to-reduce-mischaracterization-of-active-surveillance-and-focal-therapy-candidates-with-occult-higher-risk-disease/356684.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn Holloway","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the pilot study aim to address in AS and FT candidates?","Question",{"text":63,"@type":64},"The study targets mischaracterization of disease in active surveillance (AS) and focal therapy (FT) candidates, especially occult higher risk pathology that may be missed by imaging or biopsy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Who were the participants and what procedures were performed?",{"text":68,"@type":64},"The trial enrolled 20 men with low risk or favorable intermediate risk prostate cancer (Decipher score ≥ 0.45) diagnosed after an MRI-informed prostate biopsy, followed by PSMA-PET/MRI and either PET/MRI-guided biopsy or radical prostatectomy within 90 days.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main outcomes and how did the scan affect clinical decisions?",{"text":72,"@type":64},"The outcome focused on detection of higher risk disease features, and 15% detection was considered clinically significant. Average decision confidence improved from moderate to high after the scan, and major management plan changes occurred in a substantial proportion of patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356684,1790206920,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","The Prostate   \nORIGINAL ARTICLE   \nA Pilot Study of 18F‐rhPSMA‐7.3‐PET/MRI to Reduce Mischaracterization of Active Surveillance and Focal Therapy Candidates With Occult Higher Risk Disease  \nRidwan Alam1  | Derek Hesse2 | Nikki Hubbard1 | Emma McGarrity1 | Sai Kumar1 | Clayton Neill1 | Yutai Li1 | Nicole Handa1 | Hiten D. Patel1 | Edward M. Schaeffer1 | Hatice Savas2 | Ashley E. Ross1  \n1Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA | 2Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA  \nCorrespondence: Ridwan Alam ([ridwan.alam@nm.org](ridwan.alam@nm.org))  \nReceived: 18 September 2025 | Revised: 2 February 2026 | Accepted: 19 February 2026  \nFunding: a Prostate Cancer Foundation; a Developmental Research Program grant from the SPORE in Prostate Cancer, Grant/Award Number: P50 CA 180995  \nKeywords: active surveillance | focal therapy | prostate cancer | PSMA‐PET | rhPSMA  \nABSTRACT  \nIntroduction: PSMA‐PET offers an opportunity to reduce the mischaracterization of disease in active surveillance (AS) and focal therapy (FT) candidates. We describe the results of a pilot clinical trial evaluating 18F‐radiohybrid(rh)PSMA‐7 . 3‐PET/MRIto detect occult adverse pathology among potential AS and FT candidates (NCT05852041) .  \nMethods: We enrolled 20 men with low risk or favorable intermediate risk prostate cancer and Decipher score ≥ 0.45 diagnosed after an MRI‐informed prostate biopsy. All patients underwent PSMA‐PET/MRI followed by either PET/MRI‐guided biopsy or radical prostatectomy within 90 days. The outcome of interest was detection of grade group (GG) 3–5 disease, seminal vesicle invasion (pT3b), or lymph node involvement (pN1) . A detection rate of 15% for this outcome was considered clinically significant. Management decisions and confidence in those decisions were recorded before and after the scan using a 3‐point scale. A paired t‐test was performed to compare the change in confidence decisions.  \nResults: At enrollment, 17 patients (85%) had favorable intermediate risk and 3 (15%) had low risk prostate cancer. The median Decipher score was 0.58 (IQR 0.49–0.65) . Five patients (25%) demonstrated the outcome of interest based on upgrading alone. None had upstaging to pT3b or pN1 . Major changes in management plan occurred in 7 patients (35%) . Average confidence in decisions improved from moderate (2.05) to high (2.80) after the scan (p \u003C 0.001) .  \nConclusions: 18F‐rhPSMA‐7 . 3‐PET/MRI can detect occult higher risk disease in men who are otherwise candidates for AS or FT. The scan prompted major changes in management and increased confidence in the final treatment strategy.  \n1 | Introduction  \nOutcomes for localized prostate cancer vary greatly and can be prognosticated based on disease features at presentation. As such, risk stratification has become a fundamental component in the management of prostate cancer, with higher risk presentations commanding increasingly intensive therapies [1, 2] . This allows for a more tailored approach that better balances  \nthe harms and benefits of treatment at each point along the disease spectrum. In particular, the utilization of active surveillance (AS) and focal therapy (FT) for patients with favorable risk disease has played an integral role in combating the overtreatment of prostate cancer.  \nAS protocols are intentionally designed to maintain a large window of curability. Indeed, the rates of metastasis and  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s) . The Prostate published by Wiley Periodicals LLC.  \nThe Prostate, 2026; 86:865–871 865  \n[https://doi.org/10.1002/pros.70147](https://doi.org/10.1002/pros.70147)  \nprostate cancer‐specific mortality for patients on AS are exceedingly low [3] . Still,","cbCaito8H1slDD6T","https://ap.wps.com/l/cbCaito8H1slDD6T","pdf",1175039,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Background and rationale","[{\"question\":\"What problem does the pilot study aim to address in AS and FT candidates?\",\"answer\":\"The study targets mischaracterization of disease in active surveillance (AS) and focal therapy (FT) candidates, especially occult higher risk pathology that may be missed by imaging or biopsy.\"},{\"question\":\"Who were the participants and what procedures were performed?\",\"answer\":\"The trial enrolled 20 men with low risk or favorable intermediate risk prostate cancer (Decipher score ≥ 0.45) diagnosed after an MRI-informed prostate biopsy, followed by PSMA-PET/MRI and either PET/MRI-guided biopsy or radical prostatectomy within 90 days.\"},{\"question\":\"What were the main outcomes and how did the scan affect clinical decisions?\",\"answer\":\"The outcome focused on detection of higher risk disease features, and 15% detection was considered clinically significant. Average decision confidence improved from moderate to high after the scan, and major management plan changes occurred in a substantial proportion of patients.\"}]","A Pilot Study of 18F‐rhPSMA‐7.3‐PET/MRI to Reduce Mischaracterization of Active Surveillance and Focal Therapy Candidates With Occult Higher Risk Disease | PDF",1790126794,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2015093abddd68f1136b0ce165144d3d.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4bd4aa7b230b6b2c7df497f4edb05cb9.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2611e2393999156f82ca765aafe2a512.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/023f038d3a98f59f0ad719b318736214.webp",980,1287]